Cathay Biotech announced that the operating revenue for 2024 is expected to be 2.958 billion yuan, a year-on-year increase of 39.91%. The net profit attributable to shareholders of the listed company is expected to be 489 million yuan, a year-on-year increase of 33.41%. It is proposed to distribute a cash dividend of 4 yuan for every 10 shares to all shareholders